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may reflect more effective population targeting and improved instrument 
coverage. Additional research will determine whether the two subscale structure 
of the NEI VFQ-25-R provides better interpretability of potential differences in 
patient-reported visual functioning than the NEI VFQ-25.  
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OBJECTIVES: This study aimed to assess the patient perception about brand 
name and generic drugs and to identify clusters with different preferences, and 
to evaluate the willingness to pay for a brand-name drug over a generic 
alternative. METHODS: A cross-sectional survey was conducted through self-
administered, online questionnaire. The questionnaire comprised 27 items, 
which included several attributes of pharmaceutical products like therapeutic 
efficacy, brand, price and source of information. Questionnaire also included 4 
hypothetical scenarios to ask about patients’ preferences to purchase brand-
name drugs over generic drugs and vice versa. Descriptive statistics were used to 
examine characteristics of the participants and to summarize our results. 
Preference clusters were identified, individual level utility functions were 
estimated and the willingness to pay for a brand name drug over a generic 
alternative. RESULTS: The usable response rate was 68%. The mean age of the 
respondents was approximately 29 years (range 18-68 years). Most respondents 
believed that generic drugs were less expensive (91.8%) and therapeutically 
effective (72.2%) than brand-name drugs, but only 52.2% preferred to take generic 
drugs themselves. Four clusters with distinctive individual level preferences with 
some differences in socioeconomic background were identified. About half of the 
respondents were price sensitive. Approximately 62% of the respondents were 
willing to take brand-name drugs for chronic diseases such as cardiovascular 
and respiratory diseases. 74% respondents preferred to purchase over the 
counter generic drugs for general ailments such as headache, sore throat and 
fever. Few respondents had preferences such as specific brand or to have a 
pharmacist or a physician as an information source for buying over the counter 
drugs. CONCLUSIONS: These findings provided new information on the 
consequent effects of price, efficacy, counseling, brand and other product 
characteristics on the choice by patients between branded and generic drug.  
 
PRM133  
FREQUENCY AND EFFECT SIZES OF RISK FACTORS ASSOCIATED WITH INITIAL 
MEDICATION ADHERENCE  
Zeber JE1, Williams AF2, Manias E3, Peterson AM4, Roberts CS5, Hutchins D6, Udezi AW7 
1Scott & White Healthcare, Temple, TX, USA, 2Monash University, Frankston Australia, 
Australia, 3University of Melbourne, Carlton, Victoria, Australia, 4University of the Sciences, 
Philadelphia, PA, USA, 5Pfizer, New York, NY, USA, 6Caremark, Scottsdale, AZ, USA, 
 7University of Benin, Benin City, Edo, Nigeria  
OBJECTIVES: Initial medication adherence, filling pharmacy scripts when first 
prescribed to begin a regimen, is an important yet understudied area. Long-term 
outcomes for chronically ill patients are dependent upon this critical early 
treatment phase. Recognizing how research findings can inform subsequent 
translation into effective clinical practices, this study summarizes the current 
literature on behavioral and psychosocial risk factors affecting initial medication 
adherence. METHODS: An international working group conducted a 
comprehensive systematic review utilizing multiple search terms for patient, 
provider or organizational factors associated with initial adherence. Following 
rigorous efforts limiting inclusion to studies targeting initial adherence versus 
broader or more ambiguous early treatment periods, we reviewed publications 
presenting primary data from 1966-2012. Eligible articles were abstracted 
documenting terminology, methodological approaches, and factors associated 
with adherence problems. We noted the frequency that unique risk factors were 
analyzed and their relative effect sizes calculated by the study authors. 
RESULTS: Only 24 publications met eligibility criteria from 865 potentially 
relevant publications. The diverse papers covered an array of study designs, 
anaytic techniques, and populations (7 countries, sample sizes 60–5.2 million), 
utilizing administrative datasets and self-reported surveys. Several articles 
modelled numerous risk factors yet others focused on single variables. The most 
prevalent factor (n=16) was specific medication or drug class (OR range  
1.50–4.87), followed by 14 papers reporting comorbodities or illness severity (ORs 
1.40–2.78); 11 articles noted medication cost effects (ORs 1.20–7.30). Less 
frequently cited were socioeconomic status, physician characteristics or 
medication beliefs, factors magnifying adherence problems up to six-times. 
CONCLUSIONS: Attention to critical influences upon adherence during the initial 
treatment course is imperative to improving outcomes. Evolving research efforts 
into associations between initial adherence and numerous risk factors can 
highlight contributions towards beneficial interventions. Multidisciplinary 
approaches, particularly those tailored to specific risks and patient preferences, 
may help reconcile potential barriers while establishing positive longitudinal 
medication behavior.  
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OBJECTIVES: The time trade-off (TTO) and the standard gamble (SG) are 
instruments that can be administered to patients in the direct elicitation of 
health utilities (HU). A previous systematic review of the literature (56 relevant 
publications, 79 study arms and 26 disease categories) indicated significant 
overall correlation in patient-elicited HU between TTO and SG. The present 
analysis further examined the correlation between TTO and SG within specific 
subgroups from the previous analysis. METHODS: Correlation between mean or 
median TTO and SG was explored by Spearman’s rank correlation test, when a 
sufficient number of study arms were available, for the following subgroups: 
incremental HU, disease, gender, age, income, education level and employment 
status. All comparisons were undertaken by sorting the mean or median HU 
values according to TTO, in increasing order by increments of 0.10. RESULTS: For 
the incremental analysis of mean TTO versus SG, significant positive correlation 
was observed when HU values were greater than 0.6 (r=0.687), 0.7 (r=0.478) and 
0.8 (r=0.525) or lower than 0.7 (r=0.564); no significant correlation was observed 
for HU values lower than 0.6 (r=0.7 with post-hoc analyses identifying the 
scarcity of studies as a plausible reason) or greater than 0.9 (r= -0.037). Overall 
mean SG was greater than overall mean TTO for all disease subgroups except 
HIV, with significant positive correlations observed in two diseases: 
cardiovascular disease (r=0.929) and ocular disease (r=0.504). Significant positive 
correlation was observed in both subgroups of females (r=0.814) and males 
(r=0.738). The series of subgroup analyses pertaining to median incremental HU 
values yielded findings similar to those in the analysis of means. CONCLUSIONS: 
The correlation between patient-reported TTO and SG outcomes was observed 
for numerous demographic and analytical subgroups. The occurrence of 
correlation may be more widespread than observed, given the limitations 
imposed by the existing study arm sample.  
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OBJECTIVES: Work disability is known to seriously impair individual quality of 
life and to cause considerable societal costs, primarily due to medical treatment 
and vocational rehabilitation. Following the WHO model of “disease - functional 
limitation - work disability”, we analyzed the longitudinal effects of perceived 
current health and functional limitations on future work disability. METHODS: In 
2007, two adult sub-samples of the Kantar Health European Healthcare Panel in 
Germany and UK were surveyed (n=4.008), and self-reports about perceived 
health status (SF-12), 24 different disease conditions and occupational status 
were collected. In 2012 the participants were re-contacted and completed a 
health status and work disability questionnaire. Careful panel management and 
quota adjustment ensured the representativeness of the samples for the 
populations in the countries. RESULTS: In 2007, 48.1% of the sample was full-
time (GER: 57.4%; UK: 38.9%) and 12.5% part-time (GER: 10.6%; UK: 14.5%) 
employed. Five years later, in 2012, 19% of the previously full- or part-time 
employed individuals were no longer employed due to health reasons. Health 
related unemployment in 2012 was highly correlated with general health status 
(gamma: 0.70; p<0.01) and functional limitations as measured by the SF-12 
subscale in 2007(=0.39; p>0.01). Of those still employed in 2012, 16.2% were 
impaired in their jobs. Most frequently they had to take breaks more often (7.5%), 
were restricted in performing typical elements of work (6.1%) or required special 
tools (2.7%). CONCLUSIONS: Future amount and nature of work disability of a 
workforce can be predicted by using conventional measures of perceived health 
and functional status. The potential use of prognostic considerations to assess 
the need for preventive and rehabilitative measures will be discussed.  
 
PRM136  
THE PATIENT PERCEPTION OF INTENSITY OF URGENCY SCALE (PPIUS): ITS 
VALIDATION IN MEN WITH LOWER URINARY TRACT SYMPTOMS (LUTS) 
ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA (BPH)  
Mathias SD1, Crosby R1, Klaver M2, Drogendijk T2, Hakimi Z2, Odeyemi IA3 
1Health Outcomes Solutions, Winter Park, FL, USA, 2Astellas Pharma Global Development, 
Leiden, The Netherlands, 3Astellas Pharma Europe Ltd, Chertsey, UK  
OBJECTIVES: The PPIUS is a single-item patient-reported rating scale capturing 
degree of urgency associated with micturition and/or incontinence. We 
evaluated its measurement properties in patients with lower urinary tract 
symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). METHODS: 
Subjects enrolled in a Phase II, randomized, double-blind, 12-week study of fixed 
dose combinations of solifenacin with tamsulosin in an Oral Control 
Administration System (OCASTM) formulation TOCAS monotherapy, and placebo 
completed several disease specific patient reported outcomes and rated their 
level of urgency at every micturition and number of incontinence episode using 
the PPIUS prior to visits 2 (baseline), 3, 4, and 6 (end of study [EOS]). Six different 
scores were derived from the PPIUS including the mean, maximum, Total 
Urgency and Frequency Score (TUFS)* (defined as average sum of urgency 
episodes during a 24 hour period), number of urgency episodes, number of 
severe urgency episodes, and number of urge incontinence episodes. 
Measurement properties, including reliability, validity and responsiveness, were 
assessed. RESULTS: 1,010 males (mean age: 66) were enrolled. Intra class 
correlations (test-retest reliability) exceeded 0.70 for all scores. All PPIUS scores 
at Visit 2 and EOS were significantly (p<0.001) different for those above/below the 
median on International Prostate Symptom Score (IPSS) storage scores, but TUFS 
and number of urgency episodes had highest partial eta-squared values 
indicating these scores demonstrated the greatest ability to discriminate 
between groups differing in baseline severity (known groups validity). Three 
PPIUS scores (maximum, TUFS and urgency episodes) showed notably higher 
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values across all four responsiveness measures. Findings were similar in the 
subgroup of patients with high storage symptoms at baseline. CONCLUSIONS: 
This large study provided a comprehensive examination of the measurement 
properties of the PPIUS. The TUFS provided an excellent combination of 
measurement properties and is therefore considered one of the most appropriate 
PPIUS endpoint for use in studies of patients with LUTS associated with BPH.  
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OBJECTIVES: To understand how individuals value information from diagnostic 
technologies, we reviewed and analyzed published willingness-to-pay (WTP) 
studies on the topic. METHODS: We searched PubMed for English-language 
articles related to the WTP for diagnostic laboratory tests published from 1985 
through 2011. We characterized methodological differences across studies, 
examined individual- and technology-level factors associated with WTP, and 
summarized median WTP values across different diagnostic tests. RESULTS: We 
identified 66 relevant WTP studies. Half focused on oncology, while the 
remainder analyzed infectious diseases (16.1%) and obstetric or gynecological 
conditions (11.7%) among other areas. Most laboratory tests investigated in 
studies were biological samples/genetic testing (61.1%) or imaging tests (31.9%). 
Roughly one-third of the analyses (30.3%) used discrete-choice questions to elicit 
WTP, while others used payment cards (15.2%) and bidding games (13.6%). Of the 
44 studies with median WTP values available, most reported values below $100, 
though there was substantial variation in some technologies (e.g., median WTP 
for colon or colorectal cancer screening ranged from below $100 to over $1,000). 
Patient factors associated with higher WTP for diagnostic information included 
higher income, education, disease severity, perceived disease risk, and family 
history. More severe conditions and diseases without a controllable risk factor, 
such as some cancers and congenital abnormalities, were associated with higher 
WTP estimates. More accurate tests appeared to have higher WTP. 
CONCLUSIONS: The contingent valuation literature in diagnostics has grown 
rapidly, and suggests that respondents may place considerable value on 
diagnostic information. However, there exists great variation in studies with 
respect to the type of technologies and diseases assessed, respondent 
characteristics, and methodology used. The perceived value of diagnostic 
technologies is also influenced by the study design and elicitation methods.  
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OBJECTIVES: To summarize the magnitude of placebo effects on patient-
reported physical and mental health outcomes in well-controlled drug trials. 
METHODS: We conducted a systematic review of randomized, double-blind, 
placebo-controlled drug trials via PubMed and supplemental sources published 
over a 12-year period (1/1/1995-12/31/2011) with documentation of full Medical 
Outcomes Study short-form 36 (SF-36) scores by treatment group. Standardized 
effects (SE=change/general population SD) for SF-36 physical and mental 
component summary score (PCS, MCS) changes were computed from baseline to 
endpoint for each treatment arm. SE was evaluated versus Cohen’s dcutoffs 
(small ≤0.30, medium 0.30 to 0.80, and large SE ≥0.80), as well as currently 
recommended minimum important difference (MID) thresholds of 0.3 and 0.5 SD 
units. RESULTS: The search identified 805 publications, 150 of which were well-
controlled and sufficiently documented drug trials for 35 heterogeneous medical 
conditions. Sample sizes varied with IQR: 67-448 (median= 205). The majority  
of trials, 107 (71.3%) reported small SE for PCS or MCS. Medium placebo effects 
were reported in 37 trials (25%). Large SE were reported in just 6(4%) trials.  
In contrast, clinically effective drug treatment arm effects were more often 
medium (51/103;50%) and large(19/104;18%). Median SE for placebo arms across 
all trials for PCS was 0.11(IQR: 0.00 to 0.26), for MCS (median=0.06, IQR: -0.05 to 
0.21). Mean placebo changes met the 0.3 MID threshold in 43 (29%) trials; 17(12%) 
met the 0.5 point threshold. CONCLUSIONS: Although placebo effects are most 
often small for patient-reported physical and mental outcomes, a noteworthy 
proportion of well-controlled trials report placebo effects achieving the 0.3 SD 
MID threshold. Therefore, we recommend evaluating MID for single group 
comparisons (of controlled or observational data), with a 0.5 SD cutoff, and for 
controlled trial findings expressed as net of placebo changes, with a smaller 0.3 
SD cutoff.  
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OBJECTIVES: The follow-up rate of socioeconomically at risk children with vision 
diseases is only 5% at our eye institution. Through the Children’s Eyecare 
Adherence Project (CECAP), we identified barriers to care in this population and 
developed a conceptual framework as well as parent/caregiver questionnaire. 
METHODS: Barriers to follow-up were obtained by two trained medical students 
who phoned parents/caregivers of high-risk Philadelphia schoolchildren 
identified in 2010-2011 as having eye problems requiring a follow up visit within 
1 year through our mobile outreach van and annual Give Kids Sight Day exams. 
Barriers were then organized into a conceptual framework depicting main 
themes and inter-relationships. RESULTS: Ninety-three parents/caregivers were 
phoned with ten barriers to follow-up identified and organized into 3 main 
themes: 1) predisposing factors (lack of awareness, perceived importance, 
conflict of commitment, lack of communication means); 2) system factors (lack 
of referral, clinical scheduling difficulty, lack of transportation access); 3) 
financial factors (lack of insurance, health care payment difficulty, 
transportation payment difficulty). A 13-item (12 dichotomous, 1 open-ended) 
questionnaire was developed encompassing these 10 barriers for administration 
to parents/caregivers. CONCLUSIONS: The resulting CECAP parent/caregiver 
survey is brief and of use for future patient support and outreach programs of 
children with vision diseases. Ongoing work involves validating this survey 
through a larger study of children identified in 2012 as needing follow up.  
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OBJECTIVES: The common international standard for measuring health benefit 
within economic evaluation requires the use of generic preference-based health-
related quality of life (HRQoL) instruments. The availability of multiple 
instruments raises questions about their relative merits and recent studies have 
highlighted the paucity of evidence regarding measurement properties in the 
context of spinal cord injury (SCI). As part of a mixed-methods research 
program, this qualitative study explores the appropriateness of 6 established 
instruments for use in SCI populations. METHODS: Individuals living with SCI 
were invited to participate in one of three focus groups (n=15). Eligible 
participants were identified from Vancouver General Hospital’s Spine Program 
database; purposive sampling was used to ensure that a range of demographic 
and injury-related characteristics were represented. Perceptions and opinions 
were solicited on the following questionnaires: 15D, Assessment of Quality of 
Life (AQoL-8D), EQ-5D-5L, Health Utilities Index, self-administered Quality of 
Well-Being Scale, and SF-36v2. Framework Analysis was used to evaluate the 
qualitative information gathered during discussion. Strengths and limitations of 
each questionnaire were thematically identified and managed using NVivo 
software. RESULTS: Major emergent themes were (i) general perceptions, (ii) 
comprehensiveness, (iii) content, (iv) wording, and (v) features. Two sub-themes 
pertinent to content were also identified; ‘questions’ and ‘options’. All focus 
group participants perceived the AQoL-8D to be the most relevant instrument to 
administer to an SCI population. This measure was widely considered to be 
comprehensive, with relevant content (i.e. wheelchair inclusive) and applicable 
items. Participants had mixed perceptions about the other 5 questionnaires, 
albeit to varying degrees. CONCLUSIONS: The 35-item AQoL-8D was consistently 
viewed as the most appropriate preference-based HRQoL instrument for 
individuals living with SCI. Despite a strong theoretical underpinning, AQoL 
instruments are infrequently used in North America and further empirical 
research is necessary to build on these encouraging qualitative findings.  
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OBJECTIVES: The objective of this study is to quantify utilities loss in men and 
women affected by HPV-induced pathologies in Italy. METHODS: A multicentre, 
retrospective study was designed to enroll a cohort of males and females with 
HPV-related diseases who were detected and managed in the preceding 18 
months. Utilities were calculated using the Time Trade-Off (TTO) method. The 
elicitation of utilities was performed using a validated algorithm [Mennini et al. 
Clin Ther 2011 ] specifically developed to the computer-guided and standardized 
administration of a TTO questionnaire. Utilities associated with each of the 
following pathologies were assessed: atypical squamous cells of undetermined 
significance (ASCUS), cervical intraepithelial neoplasia (CIN) grade 1, CIN grade 
2-3 and cervical cancer in women; anogenital warts, anal cancer and head and 
neck cancer both in men and women. The European Quality of Life questionnaire 
(EQ-5D) was used to assess the baseline health conditions of respondents. 
RESULTS: On 450 enrolled patients, 421 (mean age 44.9±16.5 years) responded, 
providing an overall response rate of 93.6%. The patients’ perception of their 
health state was rather high (EQ-5D score ranged between 1 and 0.8), with the 
exception of patients affected by anal cancer patients (EQ-5D corresponding to 
0.6±0.3). The mean utility value by HPV-induced pathology corresponded to 
0.77±0.27, 0.71±0.29, 0.83±0.22, 0.81±0.27, 0.58±0.31, 0.51±0.26 and 0.69±0.30 for 
ASCUS, CIN1, CIN2-3, invasive cervical cancer, anogenital warts, anal cancer and 
head and neck cancer, respectively. The regression analysis showed that only 
the pathological condition influences the estimated utility value. CONCLUSIONS: 
Patients' health-state preference is a variable with a high impact on economic 
evaluations. The measurement of each utility relied on a solid and well 
recognized procedure. This multicenter study elicited utilities in a wide range of 
HPV-induced pathologies and in a large sample size as well.  
